

COPY OF PAPERS
ORIGINALLY FILED

ATTORNEY'S DOCKET NO. M0656/7064(HCL)

RECEIVED

MAR 22 2002

TECH CENTER 1600/2900

Applicant(s): Gertler et al.
Serial No.: 09/823,240
Confirmation No.: 6318
Filed: March 30, 2001
For: METHODS AND PRODUCTS FOR REGULATING CELL MOTILITY
Examiner: Unassigned
Art Unit: 1645

CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, Washington, D.C. 20231, on the 11 day of March, 2002.


Helen C. Lockhart

COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

Sir:


Transmitted herewith is/are the following document(s):

- [x] Supplemental Information Disclosure Statement
- [x] Form PTO1449
- [x] Cited References
- [x] Certificate of Mailing
- [x] Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 720-3500, Boston, Massachusetts.

No check is enclosed. If a fee is required, the balance may be charged to the account of the undersigned, Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully Submitted,


Helen C. Lockhart
Reg. No. 39,248
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, MA 02210-2211
(617) 720-3500

Docket No. M0656/7064(HCL)
Date: March 11, 2002
X03/21/02



COPY OF PERS
ORIGINALLY FILED

ATTORNEY'S DOCKET NO: M0656/7064(HCL)
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1645
#9
RP
3-29-02
attachment

Applicant: Gertler et al.
Serial No.: 09/823,240
Confirmation No.: 6318
Filed: March 30, 2001
For: METHODS AND PRODUCTS FOR REGULATING CELL MOTILITY
Examiner: Unassigned
Art Unit: 1645

RECEIVED

MAR 22 2002

TECH CENTER 1600/2900

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, Washington, D.C. 20231, on the 11 day of March, 2002.

Helen C. Lockhart
Helen C. Lockhart

Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL STATEMENT FILED PURSUANT TO THE DUTY OF
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed before the mailing date of a first Office Action on the merits in the above-identified case.

No fee or certification is required.

PTA

Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart application and this communication was not received by the office of the undersigned more than 30 days prior to filing of this Information Disclosure Statement.

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

The following are remarks concerning the other information cited:

PART III: Remarks

Documents cited on the attached form PTO-1449 (modified) are enclosed unless otherwise indicated on the attached form PTO-1449 (modified). It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his own conclusion regarding the relevance of the cited information.

Serial No.: 09/823,240

- 3 -

Art Unit: 1645

An early and favorable action is hereby requested.

Respectfully submitted,
Gertler et al., Applicant(s)

By: 

Helen C. Lockhart, Reg No. 39,248
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, MA 02210
Telephone (617) 720-3500

Docket No. M0656/7064
Dated: March 11, 2002
X03/21/02

MAR 22 2002

FORM PTO-1449/A and B (Modified)

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

APPLICATION NO.: 09/823,240

TECH CENTER 1600/2900
ATTORNEY DOCKET NO. 656/7064

FILING DATE: March 30, 2001

CONFIRMATION NO.: 6318

APPLICANT: Gertler et al.

GROUP ART UNIT: 1645

EXAMINER: Unassigned

Sheet MAR 21 2002 of 1

U.S. PATENT DOCUMENTS

Examiner's Initials#	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		

FOREIGN PATENT DOCUMENTS

Examiner's Initials#	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
	B3	PCT	US01/10249		International Search Report	03/30/2001	
	B4	WO	01/74378	A2	Regents of the University of CA	10/11/2001	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials#	Cite No.	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
	C6	ASZODI, A. et al., "The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function", <i>The EMBO Journal</i> , 1999, Pages 37-48, Vol. 18, No. 1, European Molecular Biology Organization		
	C7	BEAR, J.E. et al., "Negative Regulation of Fibroblast Motility by Ena/VASP Proteins", <i>Cell</i> , June 23, 2000, Pages 717-728, Vol. 101, Cell Press		
	C8	GERTLER, F.B. et al., "Mena, a Relative of VASP and Drosophila Enabled, is Implicated in the Control of Microfilament Dynamics", <i>Cell</i> , October 18, 1996, Pages 227-239, Vol. 87, Cell Press		
	C9	HAUSER, W. et al., "Megakaryocyte hyperplasia and enhanced agonist-induced platelet activation in vasodilator-stimulated phosphoprotein knockout mice", <i>Proc. Natl. Acad. Sci. USA</i> , July 1999, Pages 8120-8125, Vol. 96		
	C10	KRAUSE, M. et al., "Fyn-binding Protein (Fyb)/SLP-76-associated Protein (SLAP), Ena/Vasodilator-stimulated Phosphoprotein (VASP) Proteins and the Arp2/3 Complex Link T Cell Receptor (TCR) Signaling to the Actin Cytoskeleton", <i>The Journal of Cell Biology</i> , April 3, 2000, Pages 181-194, Vol. 149, No. 1, The Rockefeller University Press		
	C11	LIU, K. et al., "Reversible Tumorigenesis Induced by Deficiency of Vasodilator-Stimulated Phosphoprotein", <i>Molecular and Cellular Biology</i> , May 1999, Pages 3696-3703, Vol. 19, No. 5, American Society for Microbiology		
	C12	MACHESKY, L.M., "Putting on the Brakes: A Negative Regulatory Function for Ena/VASP Proteins in Cell Migration", <i>Cell</i> , June 23, 2000, Pages 685-688, Vol. 101, Cell Press		
	C13	REINHARD, M. et al., "Actin-based motility: stop and go with Ena/VASP proteins", <i>TRENDS in Biochemical Sciences</i> , April 2001, Pages 243-249, Vol. 26, No. 4		

EXAMINER

DATE CONSIDERED

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and
relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).